Cargando…

Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer

Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravi, Ananth, Reilly, Raymond M., Holloway, Claire M. B., Caldwell, Curtis B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299315/
https://www.ncbi.nlm.nih.gov/pubmed/22518303
http://dx.doi.org/10.1155/2012/545034
_version_ 1782226107015102464
author Ravi, Ananth
Reilly, Raymond M.
Holloway, Claire M. B.
Caldwell, Curtis B.
author_facet Ravi, Ananth
Reilly, Raymond M.
Holloway, Claire M. B.
Caldwell, Curtis B.
author_sort Ravi, Ananth
collection PubMed
description Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided surgery (RIGS) to guide the detection and delineation of tumours intraoperatively. The 3D point-response function of a commercial gamma-ray-detecting probe (GDP) was determined as a function of radionuclide ((131)I, (111)In,( 99m)Tc), energy-window threshold, and collimator length (0.0–3.0-cm). This function was used to calculate the minimum detectable tumour volumes (MDTVs) and the minimum tumour-to-background activity concentration ratio (T:B) for effective delineation of a breast tumour model. The GDP had larger MDTVs and a higher minimum required T:B for tumour delineation with (131)I than with (111)In or (99m)Tc. It was shown that for (111)In there was a benefit to using a collimator length of 0.5-cm. For the model used, the minimum required T:B required for effective tumour delineation was 5.2 ± 0.4. RIGS has the potential to significantly improve the accuracy of breast-conserving surgery; however, before these benefits can be realized, novel radiopharmaceuticals need to be developed that have a higher specificity for cancerous tissue in vivo than what is currently available.
format Online
Article
Text
id pubmed-3299315
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32993152012-04-19 Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer Ravi, Ananth Reilly, Raymond M. Holloway, Claire M. B. Caldwell, Curtis B. Int J Mol Imaging Research Article Breast-conserving surgery involves completely excising the tumour while limiting the amount of normal tissue removed, which is technically challenging to achieve, especially given the limited intraoperative guidance available to the surgeon. This study evaluates the feasibility of radioimmunoguided surgery (RIGS) to guide the detection and delineation of tumours intraoperatively. The 3D point-response function of a commercial gamma-ray-detecting probe (GDP) was determined as a function of radionuclide ((131)I, (111)In,( 99m)Tc), energy-window threshold, and collimator length (0.0–3.0-cm). This function was used to calculate the minimum detectable tumour volumes (MDTVs) and the minimum tumour-to-background activity concentration ratio (T:B) for effective delineation of a breast tumour model. The GDP had larger MDTVs and a higher minimum required T:B for tumour delineation with (131)I than with (111)In or (99m)Tc. It was shown that for (111)In there was a benefit to using a collimator length of 0.5-cm. For the model used, the minimum required T:B required for effective tumour delineation was 5.2 ± 0.4. RIGS has the potential to significantly improve the accuracy of breast-conserving surgery; however, before these benefits can be realized, novel radiopharmaceuticals need to be developed that have a higher specificity for cancerous tissue in vivo than what is currently available. Hindawi Publishing Corporation 2012 2012-02-20 /pmc/articles/PMC3299315/ /pubmed/22518303 http://dx.doi.org/10.1155/2012/545034 Text en Copyright © 2012 Ananth Ravi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ravi, Ananth
Reilly, Raymond M.
Holloway, Claire M. B.
Caldwell, Curtis B.
Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title_full Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title_fullStr Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title_full_unstemmed Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title_short Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer
title_sort feasibility evaluation of radioimmunoguided surgery of breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299315/
https://www.ncbi.nlm.nih.gov/pubmed/22518303
http://dx.doi.org/10.1155/2012/545034
work_keys_str_mv AT raviananth feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer
AT reillyraymondm feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer
AT hollowayclairemb feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer
AT caldwellcurtisb feasibilityevaluationofradioimmunoguidedsurgeryofbreastcancer